Previous 10 | Next 10 |
CORAL GABLES, FL / ACCESSWIRE / October 23, 2018 / The stock market turned bearish during the early morning hours. International concern drove futures lower before the opening bell on Tuesday. Many investors have begun flocking to safe haven stocks for more protection to their portfolios. ...
TRPX +62% on bid from FSD Pharma. More news on: Therapix Biosciences, Regulus Therapeutics, Correvio Pharma Corp., Stocks on the move, , Top stock market news, Read more ...
Top Gainers: RGLS +42.1% . CDNS +9.0% . SENS +7.5% . SSNC +6.3% . I +3.4% . More news on: Regulus Therapeutics, Cadence Design Systems, Inc., Senseonics Holdings, Stocks on the move, , News on ETFs, Top stock market news, Read more ...
LA JOLLA, Calif. , Oct. 22, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical data regarding RGLS4326, a s...
LA JOLLA, Calif. , Oct. 18, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it received notice from The Nasdaq Stock Market LLC "NAS...
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oxford Immunotec Global PLC (NASDAQ:OXFD), Ascena Retail Group, Inc. (NAS...
LA JOLLA, Calif. , Oct. 4, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that at the special meeting of stockholders, held September ...
LA JOLLA, Calif. , Oct. 2, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Reg...
Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals...
LA JOLLA, Calif. , Sept. 27, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...